We studied the effect of the CD34 ؉ cell dose on transplant-related mortality (TRM) and survival in 39 patients randomized to receive lenograstim-mobilized PBSCT (n = 20) or BMT (n = 19) from HLA-identical siblings. Both marrow and blood were harvested, and one infused in a double-blind fashion. The median nucleated 
ment-related factors, its incidence ranges from under 10% to over 50%. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] A number of these factors are biologic characteristics of the patient and the underlying disease, and are not modifiable. 15 Factors such as the conditioning regimen, graft-versus-host disease (GVHD) prophylaxis, and supportive therapy, on the other hand, can potentially be manipulated to improve the results of transplantation.
The quantity of cells infused during the transplant is a modifiable variable which affects the outcome of autologous and allogeneic transplantation. [14] [15] [16] [17] [18] [19] Higher infused total nucleated cell (TNC) doses result in lower TRM and improved survival after autologous 15, 19 and T cell nondepleted allogeneic 14, 16, 18, 19 bone marrow transplantation (BMT). Graft size may be better reflected by the number of CD34 ϩ cells than the TNC content. A positive relationship between the number of CD34 ϩ cells infused and improved TRM has been noted after T cell-depleted BMT from HLAidentical siblings. 17 There are no data showing the effect of CD34 ϩ cell numbers on TRM after T cell non-depleted BMT or peripheral blood stem cell transplantation (PBSCT). While 2-3 ϫ 10 8 /kg is commonly used as an 'adequate' TNC dose for allogeneic BMT, there is no established minimum dose of CD34 ϩ cells for T cell non-depleted allografts. We have performed a randomized, double-blind study comparing allogeneic BMT and PBSCT in hematologic malignancies. 20 With the availability of prospectively collected data of the various cell subpopulations constituting the graft, 21 we attempted to examine the relationship between the number of CD34 ϩ cells infused and TRM.
Patients and methods
Forty-one patients and their HLA-identical sibling donors were enrolled on the study at the Royal Marsden Hospital, Surrey, UK between June 1995 and August 1997. Patients were aged 15-55 years with hematologic malignancies requiring allogeneic hematopoietic stem cell transplantation, and had HLA-identical sibling donors. Donors gave both bone marrow (BM) and blood stem cells (PBSC); one of the products was infused and the other kept in storage in a double-blind fashion. One donor withdrew from the study after enrollment but before donating stem cells, and one patient was withdrawn after the donor had been har-vested but before randomization because of refractory relapse requiring salvage chemotherapy instead of transplantation. These two patients have been excluded from all analyses. Table 1 shows the characteristics of the remaining 39 patients. Nineteen patients underwent BMT and 20 underwent PBSCT. The groups were essentially comparable although there was a higher proportion (P = NS) of patients with high-risk disease in the PBSCT group. Patients with acute leukemia in first remission and chronic myeloid leukemia (CML) in the first chronic phase were considered low-risk, whereas all others were considered high-risk.
The study protocol was approved by the institutional review boards (Scientific and Ethics Committees) of the Royal Marsden Hospital, and all patients and donors provided informed consent.
Marrow harvest and leukapheresis
BM was collected using standard procedures under general anesthesia with a target nucleated cell count of 3 ϫ 10 8 cells/kg (all weights refer to the actual recipient body weight unless specified otherwise). This relatively high target was chosen because a low cell dose affects the outcome of autologous as well as allogeneic transplantation adversely. [14] [15] [16] [17] [18] [19] From the next day, 10 g/kg actual donor body weight glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF, lenograstim; Granocyte, Chugai Pharma, London, UK ) was administered subcutaneously in the morning daily for 5 days. On the fifth day, 2-3 h after the last lenograstim injection, leukapheresis was performed using a Cobe Spectra continuous-flow cell separator (Cobe Laboratories, Lakewood, CO, USA). The volume of blood processed was the greater of 10 liters or 200% of the calcu- 
Cryopreservation, storage and infusion of stem cells
The blinding and randomization procedure has been described elsewhere in detail. 20 The products were processed to achieve a similar appearance to maintain blinding. 20 The cells were cryopreserved with DMSO using a rate-controlled freezer and were stored in the vapor phase of liquid nitrogen. At the time of the transplant, the bags were thawed in warm water (37°C) and infused immediately without manipulation. Counts were not repeated on thawed cells.
Conditioning regimens
Patients with CML received busulfan (4 mg/kg/day, days Ϫ7 to Ϫ4) and cyclophosphamide (60 mg/kg/day, days Ϫ3 and Ϫ2). 22 Acute lymphoblastic leukemia (ALL) patients who were treated on the United Kingdom Medical Research Council's ALL 12 protocol or on the sequential high-dose therapy program of the Royal Marsden Hospital 23, 24 received etoposide (60 mg/kg, day Ϫ3) and a single fraction of 1050 cGy total-body irradiation (TBI; day 0) delivered at a slow dose rate (3-4 cGy/min) from opposing 60 Co sources. All other patients received melphalan (110 mg/m 2 , day Ϫ1) and single-fraction 950 cGy TBI (day 0) delivered as above. 25, 26 Cell were infused on day 0. Randomization was stratified by conditioning regimen: melphalan-TBI, busulfan-cyclophosphamide, and etoposide-TBI.
Graft-versus-host disease prophylaxis
GVHD prophylaxis comprised cyclosporine and methotrexate (15 mg/m 2 on day 1, and 10 mg/m 2 on days 3, 6 and 11). 27 Intravenous cyclosporine was started at 3 mg/kg/day on day Ϫ1 and was switched to oral administration (12.5 mg/kg/day) at discharge. The dose was tapered by 5% per week from day ϩ50 onwards and the drug was discontinued on day 180 in the absence of chronic GVHD requiring therapy. Acute GVHD was graded according to standard criteria, 28 and overall grade II or higher GVHD treated with 500 mg/m 2 methylprednisolone intravenously daily for 3 days which was then stopped or tapered depending upon response.
Supportive therapy
Growth factors were not administered routinely post transplant. Irradiated packed red cells and platelets were given to keep the hemoglobin above 9 g/dl and platelets above 20 ϫ 10 9 /l. Broad-spectrum intravenous antibiotics (aminoglycosides and piperacillin-tazobactam) were used for sustained pyrexia of greater than 38°C, with added vancomycin for suspected or proven line infections. Amphotericin B or amphotericin B lipid complex (Abelcet, The Liposome Company, Princeton, NJ, USA) were administered for suspected or confirmed fungal infections. 29 A short course of ganciclovir was administered for cytomegalovirus activation as determined by detection of antigenemia. 30 
Data management and statistical analysis
The primary aim of the study, comparing marrow and blood, has been addressed elsewhere. 20 The identity of the infused product remained blinded until a year after the last patient's transplant. The probabilities of TRM, event-free survival (EFS) and overall (OS) survival were calculated using the method of Kaplan and Meier. The groups were compared for homogeneity using the 2 test or the Wilcoxon rank-sum test.
The following factors were studied in multivariate analysis for potential effect on TRM and survival: age, sex, diagnosis, stage of the disease (high-risk vs low-risk), source of stem cells, donor-recipient blood group compatibility, conditioning regimen (TBI vs no TBI), acute GVHD, chronic GVHD, CD3 ϩ cell dose (Ͻ0.3/у0.3 ϫ 10 8 /kg), TNC dose (Ͻ4/у4 ϫ 10 8 /kg) and the CD34 ϩ cell dose (Ͻ2/у2 ϫ 10 6 /kg). While Ͻ2/у2 was chosen as the CD34 ϩ cell dose cut-off for analysis because it was close to the median, the analysis was also repeated with Ͻ3/у3 because this cut-off was associated with greater disparities in outcome. All data are current as of May 1999.
Results
As Table 1 shows, a number of non-significant differences were seen between patients receiving Ͻ2 ϫ 10 6 CD34
ϩ Bone Marrow Transplantation cells/kg vs those receiving у2: the former tended to be younger, had a higher proportion of acute leukemia, a lower proportion of CML, and a greater proportion received TBI (related to the underlying diagnosis).
Cell quantities collected and infused
The median TNC, CD34 ϩ and CD3 ϩ cell doses infused for the whole group were 4.4 ϫ 10 8 /kg (range, 1.6-14.1), 1.9 ϫ 10 6 /kg (range, 0.6-12.3), and 0.76 ϫ 10 8 /kg (range, 0.07-3.2), respectively. Table 2 shows the cell quantities infused (19 BM and 20 PBSC; total 39 products) and collected (both products for all 39 recipients; total 78 products) separately. The number of TNC, CD34
ϩ and CD3 ϩ cells received by PBSC recipients was significantly higher. The number of these cells collected from the blood for all 39 donors was also significantly higher (Table 2) . 21 As Table 2 shows, while most BM harvests contained у1 ϫ 10 6 CD34 ϩ cells/kg, only one-fifth contained у2. On the other hand, 75% of the infused and 87% of the harvested aphereses contained у2 ϫ 10 6 CD34 ϩ cells/kg, and 60% of the infused and 72% of the harvested aphereses contained у3 ϫ 10 6 CD34 ϩ cells/kg (Table 2) .
Hematologic recovery
Neutrophil as well as platelet recovery was significantly faster after PBSCT; this has been dealt with elsewhere in depth. 20 No strong (inverse) relationship emerged between CD34 ϩ cell dose and recovery of neutrophils to 0.5 ϫ While hematologic recovery appeared to be more rapid for patients receiving у2 ϫ 10 6 CD34 ϩ cells/kg compared with those Ͻ2 (Figures 1 and 2 ), the differences were not significant. However, hematologic recovery was significantly faster for patients receiving у3 ϫ 10 6 CD34 ϩ cells/kg compared with those receiving Ͼ3 (data not shown).
Treatment-related mortality
Thirteen patients died of transplant-related causes 15-733 (median 57) days after transplantation; six in the BM group and seven in the PBSC group (P = NS). Table 3 shows the causes of death. Ten of 20 patients receiving Ͻ2 ϫ 10 6 CD34 ϩ cells/kg died compared with three of 19 receiving у2 (P = 0.02, Figure 3 ). As Table 4 shows, irrespective of the cut-off CD34 ϩ cell dose chosen, patients receiving higher CD34 ϩ cell doses had lower TRM whereas TNC and CD3 ϩ cell doses did not influence TRM. Four of five PBSC recipients receiving Ͻ2 ϫ 10 6 CD34 ϩ cells/kg experienced TRM compared with three of 15 receiving у2 (P = 0.03). Six of 15 BM recipients receiving Ͻ2 ϫ 10 6 CD34 ϩ cells/kg experienced TRM compared with none of four receiving у2 (P = 0.2). a These three rows show medians and ranges. The remaining rows show the actual numbers and proportions of patients with the minimum specified cell yields. 
Survival
Four of the five relapsing patients (all in the BM group 20 ) died and one is alive in remission after infusion of the backup PBSC product as adoptive immunotherapy. 31, 32 Twentytwo patients are alive in remission at 20-47 months (median 33); nine BMT and 13 PBSCT recipients (P = NS).
As Figures 4 and 5 show, EFS as well as OS was significantly superior in patients receiving у2 ϫ 10 6 CD34 ϩ cells/kg compared with those receiving Ͻ2 ϫ 10 6 CD34 ϩ cells/kg. Irrespective of the cut-off CD34 ϩ cell dose chosen, patients receiving higher CD34 ϩ cell doses had superior survival whereas TNC and CD3 ϩ cell doses did not influence survival (Table 4) . 
Graft-versus-host disease
There was no difference in the incidence of acute and chronic GVHD between the BM and PBSC groups (details elsewhere). 20 The TNC, CD3 ϩ or CD34 ϩ cell doses did not affect the development of acute or chronic GVHD significantly.
Multivariate analysis
In multivariate analysis, high CD34 ϩ cell dose and lowrisk disease were found to independently influence TRM, EFS and OS favorably (Table 5) . No other factor influenced outcome independently.
When the significant variables were combined to produce four different patient categories (low-risk disease ϩ CD34 у2, n = 11; low-risk disease ϩ CD34 Ͻ2, n = 10, high-
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؉ cell yields and transplant-related mortality S Singhal et al 493 Table 3 Causes of non-relapse death risk disease ϩ CD34 у2, n = 8; high-risk disease ϩ CD34 Ͻ2, n = 10), the overall difference in outcome in terms of TRM, EFS and OS was highly significant (Figures 6-8 ).
The most dramatic difference was between the patients in whom both variables were favorable and those in whom both variables were unfavorable. The influence of the cell dose was more marked for the high-risk category than for the low-risk category (Figures 6-8 ).
Discussion
High TNC doses have been found to influence the outcome of autologous and allogeneic BMT favorably, and high CD34 ϩ cell doses have been found to influence the outcome of T cell-depleted BMT favorably. This study is the first to show that the CD34 ϩ cell dose affects the outcome of T cell non-depleted BMT as well as PBSCT. Neither the risk status (high/low) nor the CD34 ϩ cell dose influenced relapse rates which were affected only by the source of stem cells (significantly lower relapse after PBSCT). 20 The favorable effect of the CD34 ϩ cell dose on EFS and OS was dependent only upon reduction of TRM because it did not influence relapse rates. 20 The reason for the favorable influence of the CD34 ϩ cell dose is not entirely clear because, although there was an engraftment advantage for patients receiving у3 ϫ 10 6
CD34
ϩ cells/kg, no engraftment difference was detected between patients receiving у2 ϫ 10 6 CD34 ϩ cells/kg and those receiving Ͻ2. The observations made in the setting of T cell-depleted BMT were similar with CD34 ϩ cell doses Ͻ1 ϫ 10 6 /kg affecting TRM and survival adversely and doses above 2 affecting engraftment favorably. 17 It is possible that engraftment is more robust and/or immune recovery more rapid with a higher CD34 ϩ cell dose; faster lymphocyte recovery has been shown to be associated with decreased TRM as well as decreased relapse. increasing the amount of blood volume processed, it would be very easy to collect a minimum of 3 ϫ 10 6 CD34 ϩ cells/kg (or even more) for all patients. Why did the TNC quantity not influence TRM and survival here? This may partly be due to the small patient population and partly due to the fact that, after having learned the influence of the TNC dose in our own practice, we had decided upon using 3 ϫ 10 8 TNC/kg as the target marrow dose in this group of patients. This was met in 14 of the 19 patients who received marrow. In four of the remaining five, the shortfall was Ͻ20% (ie the cell dose
؉ cell yields and transplant-related mortality S Singhal et al 495 was at least 2.4 ϫ 10 9 TNC/kg). Thus the TNC doses infused here were higher than our historical numbers -and reached a range where differences were detectable only by evaluating the graft content more accurately by measuring CD34 ϩ cells. The outcome appeared to improve with a change in the CD34 ϩ cut-off from 2 to 3 (Table 4 ; curves not shown). However, the patient population was not large enough to examine the influence of even higher CD34 ϩ cell doses on outcome. It is possible that higher CD34 ϩ cell doses may be even better as has been shown with autologous PBSCT. 34 The adverse influence of high-risk disease on TRM and survival is not surprising because these patients tend to be more extensively pre-treated; a factor which influences the outcome of transplantation negatively. Even within this population, the higher CD34 ϩ cell doses appeared to confer a protective effect (Figures 6-8) . Since the outcome of the low-risk patients receiving у2 ϫ 10 6 CD34 ϩ cells/kg is already excellent, the benefits of significantly higher CD34 ϩ cell doses (5 or even higher) would be best explored in the high-risk group of patients.
There was no difference in the incidence of acute and chronic GVHD in this population of patients. 20 This could have been due to the relatively small patient population, and larger studies such as the one performed by the European Blood and Marrow Transplant Group (EBMT) will be able to settle the question of GVHD more convincingly. 35 If chronic GVHD is indeed found to be a problem, future work should be directed at strategies to control this (partial or complete T cell depletion, different post-transplant immunosuppression, longer term immunosuppression) in the setting of allogeneic PBSCT. Unless the larger studies come up with a strong clinical finding against allogeneic PBSCT, we believe our data support the argument for a change in routine practice -replacement of marrow with blood as the preferred source of stem cells for allogeneic transplantation from HLA-identical siblings for high-risk disease.
The weakness of this analysis is the underlying presumption that CD34 ϩ cells obtained from BM and blood are biologically equivalent. This is apparent from the fact that the adverse influence of the low CD34 ϩ cell dose is more striking in the PBSC group (80% vs 20% TRM) than in the BM group (40% vs 0% TRM). The only way to resolve the question of biologic equivalence would be to perform a study in which comparable CD34 ϩ cell doses are infused from BM or blood. Such a study is unlikely to be performed because it is difficult to obtain large CD34 ϩ cell doses from BM or to justify the infusion of low CD34 ϩ cell doses in PBSC recipients in the face of data showing the importance of high CD34 ϩ cell doses. We conclude that the number of CD34 ϩ cells infused affects allograft-related mortality significantly. Manipulating this number may be a way to make transplantation safer. We propose that 2-3 ϫ 10 6 CD34 ϩ cells be considered the ideal minimum dose, especially for PBSCT. Further work is required to see if, as in autologous transplantation, even higher doses of CD34 ϩ cells are more beneficial. Since this threshold is reached only in a minority of BM harvests and in almost all blood cell harvests, blood may replace marrow as the preferred source of stem cells
Bone Marrow Transplantation
for T cell non-depleted transplants from HLA-identical sibling donors.
